病理生理学
医学
炎症
重症监护医学
皮肤病科
免疫学
病理
作者
L. Tong,Rini M. Desai,Rebecca Olsen,Mitchell Davis
出处
期刊:Discovery Medicine
日期:2024-01-01
卷期号:36 (189): 1933-1933
标识
DOI:10.24976/discov.med.202436189.180
摘要
Atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, allergic contact dermatitis, and irritant contact dermatitis comprise a large proportion of chronic inflammatory dermatoses. This paper reviews the clinical presentations, pathophysiology, and therapeutics of inflammatory dermatoses, highlighting recent drug developments such as lebrikizumab for atopic dermatitis as well as deucravacitinib and spesolimab for psoriasis. Chronic inflammatory dermatoses significantly impact patient quality of life and contribute to substantial healthcare costs. Effective management of severe cases often requires systemic therapies and biological therapies. A thorough clinical evaluation with a tailored therapeutic approach is essential for delivering optimal care to individuals with chronic inflammatory skin diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI